Seattle Genetics role in evolving Cancer Treatment Technologies

Seattle Genetics is an internationally recognized company that has specialized in developing targeted cancer cures. The firm’s founder is called Clay Siegall, and he has been its chairman for the past two decades that it has been in business. Seattle Genetics has impacted the pharmaceuticals industry positively by making inventions that have transformed cancer treatment. The biotechnology firm was the first to develop a technology that is called antibody-drug conjugates (ADCs). This formula has been used in manufacturing effective cancer drugs that have less harm to patients compared to chemotherapies.

Siegall has led the company and its technicians in using the ADC technology to develop drugs such as GlaxoSmithKline, Pfizer, AbbVie, and Roche. It has managed to get FDA-approval for these cures, and has commercialized them in the United States and overseas. Clay has served as a biotechnology researcher for the past three decades. Before founding Seattle Genetics, he served organizations such as the National Institute of Health and the Bristol-Myers Squibb Pharmaceutical Research Institute. Siegall’s expertise also enabled him to be appointed to the boards of companies such as BioPharmaceuticals, Ultragenyx, and Mirna Therapeutics. He holds bachelor’s degree and a Ph.D. in zoology and genetics respectively.

The research work of Seattle Genetic has significantly improved cancer treatment across the world. Its success has facilitated the growth of Clay Siegall’s career and also earned him a lot of respect in the pharmaceuticals industry. In 2013, the researcher was appointed by Mirna Therapeutics to act as its external board member. He served as an advisor to the company on matters that dealt with the development of therapeutics that are based on micro-RNA. Siegall has invented several new products at Seattle Genetics, and he has 15 patents. The researcher has also published a couple of biotechnology-based books.

The commercialization of ADC drugs has facilitated the growth of Seattle Genetics. Over 21 drugs have been manufactured by using the technology. The biotechnology firm as earned more than $675 as revenue from selling cancer medicines in the United States and abroad. It has mobilized its researchers to focus on developing personalized treatments for the life-threatening disease.


Leave a Reply

Your email address will not be published. Required fields are marked *